ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

upadacitinib

Also written as “Upadacitinib”, “ABT-494” and “Upadacitinib 15 MG [Rinvoq]”.

Its studies are mostly in Dermatitis, Atopic · Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Alopecia Areata, led by 3 companies.

Drug pageUpadacitinib: every studyAll 98 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 18, 202264 company-led studies, 24 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only6121 open or runningphase 4since Aug 18, 2022Dec 3, 2012Nov 2026phase 3 · NCT06389136
CARE ARTHRITIS22 open or runningphase 4since Jun 6, 2024Jun 6, 2024May 2027phase 4 · NCT07018206
Modern Biosciencesits history only11 open or runningphase 1since Apr 8, 2024Apr 8, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CARE ARTHRITIS only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2016Named upadacitinibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ABT-494
  2. Jun 6, 2024First study: phase 4 study in Arthritis, PsoriaticFirst studyNCT06454188 · 100 planned · United States, Canada
  3. May 27, 2025Phase 4 study in Axial SpondyloarthritisNCT07018206 · 200 planned · United States

Ahead

  1. May 2027Primary completion: phase 4 study in Axial SpondyloarthritisNCT07018206
  2. Sep 2028Primary completion: phase 4 study in Arthritis, PsoriaticNCT06454188

TargetBeta

“Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321

Studies

All 2 CARE ARTHRITIS leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07018206Axial Spondyloarthritis · United States4Not yet recruitingMay 2027200
NCT06454188Arthritis, Psoriatic · United States, Canada4RecruitingSep 2028100

How it is read

Names in the registry

  • “Upadacitinib”, 54 entries
  • “ABT-494”, 4 entries
  • “Upadacitinib 15 MG [Rinvoq]”, 2 entries
  • “Upadacitinib (ABT-494)”, 2 entries
  • “Upadacitinib 15mg Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.